1. Academic Validation
  2. Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells

Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells

  • J Nat Prod. 2020 Aug 28;83(8):2518-2527. doi: 10.1021/acs.jnatprod.0c00613.
Chad R Schultz 1 Martin C H Gruhlke 2 Alan J Slusarenko 2 André S Bachmann 1
Affiliations

Affiliations

  • 1 Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, Michigan 49503, United States.
  • 2 Department of Plant Physiology, RWTH Aachen University, 52056 Aachen, Germany.
Abstract

The natural product allicin is a reactive sulfur species (RSS) from garlic (Allium sativum L.). Neuroblastoma (NB) is an early childhood Cancer arising from the developing peripheral nervous system. Ornithine decarboxylase (ODC) is a rate-limiting Enzyme in the biosynthesis of polyamines, which are oncometabolites that contribute to cell proliferation in NB and other c-Myc/MYCN-driven cancers. Both c-Myc and MYCN directly transactivate the E-box gene ODC1, a validated Anticancer drug target. We identified allicin as a potent ODC inhibitor in a specific radioactive in vitro assay using purified human ODC. Allicin was ∼23 000-fold more potent (IC50 = 11 nM) than DFMO (IC50 = 252 μM), under identical in vitro assay conditions. ODC is a homodimer with 12 cysteines per monomer, and allicin reversibly S-thioallylates cysteines. In actively proliferating human NB cells allicin inhibited ODC Enzyme activity, reduced cellular polyamine levels, inhibited cell proliferation (IC50 9-19 μM), and induced Apoptosis. The natural product allicin is a new ODC inhibitor and could be developed for use in conjunction with other Anticancer treatments, the latter perhaps at a lower than usual dosage, to achieve drug synergism with good prognosis and reduced adverse effects.

Figures